ORLANDO, Florida (Reuters) ? Pfizer Inc's Lipitor and AstraZeneca's Crestor cholesterol drugs, taken at their highest dose, safely reduced artery-clogging plaque in heart patients, according to data from a clinical trial presented on Tuesday.
Crestor outperformed Lipitor by some measures in the two-year study, but it is unclear whether the results will help AstraZeneca's sales force convince doctors and payers to use its drug as it competes with much cheaper generic versions of top-selling Lipitor.
"The differences between the two drugs were modest," said Dr. Stephen Nicholls, the primary investigator of the Saturn study who presented the data at the American Heart Association scientific meeting in Orlando.
Crestor has become AstraZeneca's biggest product, with annual sales on pace to exceed of $6 billion this year, but its growth and pricing are sure to be pressured by generic Lipitor, or atorvastatin.
AstraZeneca, which previously said its drug failed to demonstrate a statistically significant advantage in the study's primary plaque regression goal, was looking for a clear edge to differentiate Crestor from its chief rival when Pfizer loses U.S. exclusivity for Lipitor at the end of the month.
The results of the Saturn study may instead position Crestor as more of a niche product for high-risk patients unable to lower their cholesterol enough with other drugs.
"Clearly, generics have an important place, but there is an important place also for Crestor as well," AstraZeneca Chief Medical Officer Howard Hutchinson said.
While Astra's calculated bet to stand out when compared with Lipitor may not pay off, the data was good news for patients as both drugs reversed progression of heart disease, and that the highest doses, from which doctors often shy away over toxicity fears, proved to be safe taken for two years.
"What this study shows is that you can actually reverse the buildup of plaque in a majority of patients with coronary disease if you treat them very intensively with either of these two powerful drugs," said Dr. Steven Nissen, chief of cardiology at the Cleveland Clinic and the study's chairman.
Researchers found the safety seen with prolonged use of the drugs at the highest dose to be particularly reassuring.
The rate of heart attacks, strokes and other major adverse heart events were low for the patient population and nearly identical for the two drugs -- 7.1 percent for Lipitor and 7.5 percent for Crestor.
"In these patients in whom you're seeing a lot of regression they're not having events," Nicholls said.
"We were very struck by the fact that we could give over 1,000 patients the top doses of the most powerful statins and basically we didn't hurt anybody," Nissen added.
(Reporting by Bill Berkrot and Lewis Krauskopf; editing by John Wallace and Maureen Bavdek)
last of the mohicans last of the mohicans ryan howard meteor shower 2011 meteor shower 2011 home depot center the replacements
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.